The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective

被引：47

作者：

Liu, Jian-Jun ^{[1
]}

Foo, Joo Pin ^{[2
]}

Liu, Sylvia ^{[1
]}

Lim, Su Chi ^{[3
]}

机构：

[1] Khoo Teck Puat Hosp, Clin Res Unit, Singapore 768828, Singapore

[2] Changi Gen Hosp, Dept Med, Singapore, Singapore

[3] Khoo Teck Puat Hosp, Ctr Diabet, Singapore 768828, Singapore

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2015年 / 108卷 / 03期

关键词：

Fibroblast growth factor 21; Diabetes; Diabetes complications; Diabetes therapy; INCREASES ENERGY-EXPENDITURE; FATTY LIVER-DISEASE; SERUM FGF21 LEVELS; INSULIN SENSITIVITY; METABOLIC SYNDROME; GLUCOSE; OBESITY; EXPRESSION; RESISTANCE; INHIBITION;

D O I：

10.1016/j.diabres.2015.02.032

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fibroblast growth factor 21 (FGF21) has been well-recognized as a metabolic hormone and a promising target for treatment of metabolic diseases. The level of endogenous FGF21 is elevated in patients with impaired glucose tolerance and progressively increased from patients with overt type 2 diabetes to those with micro-and macro-vascular complications, presumably as a compensation or response to the deterioration of metabolic imbalance. A few exploratory in vivo studies, including a recent clinical trial, showed that exogenous FGF21 mimetics targeting FGF21 signaling can attain beneficial metabolic effects not withstanding the already elevated ambient FGF21 levels. In addition, some clinically available pharmacologic agents such as fenofibrates and metformin may modulate energy and macronutrients metabolism by acting through FGF21. This review mainly focuses on the role of FGF21 in development, progression and treatment of type 2 diabetes from a clinical perspective. (c) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：382 / 389

页数：8

共 66 条

[21] An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice [J].

Holland, William L. ;

Adams, Andrew C. ;

Brozinick, Joseph T. ;

Bui, Hai H. ;

Miyauchi, Yukiko ;

Kusminski, Christine M. ;

Bauer, Steven M. ;

Wade, Mark ;

Singhal, Esha ;

Cheng, Christine C. ;

Volk, Katherine ;

Kuo, Ming-Shang ;

Gordillo, Ruth ;

Kharitonenkov, Alexei ;

Scherer, Philipp E. .

CELL METABOLISM, 2013, 17 (05) :790-797

[22] A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (rhFGF21) Modified with Polyethylene Glycol [J].

Huang, Zhifeng ;

Wang, Huiyan ;

Lu, Meifei ;

Sun, Chuanchuan ;

Wu, Xiaoping ;

Tan, Yi ;

Ye, Chaohui ;

Zhu, Guanghui ;

Wang, Xiaojie ;

Cai, Lu ;

Li, Xiaokun .

PLOS ONE, 2011, 6 (06)

[23] Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21 [J].

Iglesias, Pedro ;

Selgas, Rafael ;

Romero, Sara ;

Diez, Juan J. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (03) :301-309

[24] Inhibition of growth hormone signaling by the fasting-induced hormone FGF21 [J].

Inagaki, Takeshi ;

Lin, Vicky Y. ;

Goetz, Regina ;

Mohammadi, Moosa ;

Mangelsdorf, David J. ;

Kliewer, Steven A. .

CELL METABOLISM, 2008, 8 (01) :77-83

[25] Association between serum fibroblast growth factor 21 and diabetic nephropathy [J].

Jian, Wei-Xia ;

Peng, Wen-Hui ;

Jin, Jie ;

Chen, Xue-Ru ;

Fang, Wen-Jun ;

Wang, Wei-Xing ;

Qin, Li ;

Dong, Yan ;

Su, Qing .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (06) :853-859

[26] FGF-21 as a novel metabolic regulator [J].

Kharitonenkov, A ;

Shiyanova, TL ;

Koester, A ;

Ford, AM ;

Micanovic, R ;

Galbreath, EJ ;

Sandusky, GE ;

Hammond, LJ ;

Moyers, JS ;

Owens, RA ;

Gromada, J ;

Brozinick, JT ;

Hawkins, ED ;

Wroblewski, VJ ;

Li, DS ;

Mehrbod, F ;

Jaskunas, SR ;

Shanafelt, AB .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1627-1635

[27] Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319 [J].

Kharitonenkov, Alexei ;

Beals, John M. ;

Micanovic, Radmila ;

Strifler, Beth A. ;

Rathnachalam, Radhakrishnan ;

Wroblewski, Victor J. ;

Li, Shun ;

Koester, Anja ;

Ford, Amy M. ;

Coskun, Tamer ;

Dunbar, James D. ;

Cheng, Christine C. ;

Frye, Christopher C. ;

Bumol, Thomas F. ;

Moller, David E. .

PLOS ONE, 2013, 8 (03)

[28] Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice [J].

Kim, H. W. ;

Lee, J. E. ;

Cha, J. J. ;

Hyun, Y. Y. ;

Kim, J. E. ;

Lee, M. H. ;

Song, H. K. ;

Nam, D. H. ;

Han, J. Y. ;

Han, S. Y. ;

Han, K. H. ;

Kang, Y. S. ;

Cha, D. R. .

ENDOCRINOLOGY, 2013, 154 (09) :3366-3376

[29] Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation [J].

Kim, Kook Hwan ;

Jeong, Yeon Taek ;

Kim, Seong Hun ;

Jung, Flye Seung ;

Soo-Park, Kyong ;

Lee, Hae-Youn ;

Lee, Myung-Shik .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 440 (01) :76-81

[30]

Kuro O M., Nat Rev Nephrol

← 1 2 3 4 5 6 7 →